{"id":24445,"date":"2022-11-10T15:53:00","date_gmt":"2022-11-10T07:53:00","guid":{"rendered":"https:\/\/flcube.com\/?p=24445"},"modified":"2025-01-31T15:55:30","modified_gmt":"2025-01-31T07:55:30","slug":"nmpa-conditionally-approves-yingli-pharmas-linperlisib-for-lymphoma","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=24445","title":{"rendered":"NMPA Conditionally Approves Yingli Pharma’s Linperlisib for Lymphoma"},"content":{"rendered":"\n

The National Medical Products Administration (NMPA) website indicates that linperlisib, a Category 1 anti-tumor drug, has been conditionally approved in China. The drug is developed by US-based Yingli Pharma, a firm focused on developing products for both the China and US markets. The intended indication for linperlisib is recurrent\/refractory (R\/R) follicular lymphoma (FL). Hengrui Medicine will assist in the commercialization of the drug in China.<\/p>\n\n\n\n

Linperlisib Profile<\/strong>
Linperlisib is a highly selective and potent PI3K\u03b4 inhibitor, targeting a validated pathway in lymphomas due to its critical role in cell proliferation and survival. The latest results from the Phase II clinical study of linperlisib in China for R\/R FL showed an overall response rate (ORR) of 79.8%, a disease control rate (DCR) of 96.6%, and a 12-month overall survival (OS) of 91.4%. The median time to remission (mTTR) was 1.9 months, the median progression-free survival (mPFS) was 13.4 months, and the median duration of remission (mDOR) was 12.3 months. In terms of safety, most adverse reactions were controllable, and the drug was generally well tolerated. Administered orally once per day, linperlisib offers good efficiency, safety, and medication compliance.<\/p>\n\n\n\n

Regulatory Milestones<\/strong>
Linperlisib was awarded Breakthrough Therapy status by the NMPA in 2020. The drug also holds Orphan Drug Designations from the US FDA for follicular lymphoma (FL), chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL), and T cell lymphoma. These designations highlight the drug’s potential to address significant unmet medical needs in these conditions.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

The National Medical Products Administration (NMPA) website indicates that linperlisib, a Category 1 anti-tumor drug,…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[16,15,1870],"class_list":["post-24445","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-cancer","tag-product-approvals","tag-yingli-pharma"],"yoast_head":"\nNMPA Conditionally Approves Yingli Pharma's Linperlisib for Lymphoma - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"The National Medical Products Administration (NMPA) website indicates that linperlisib, a Category 1 anti-tumor drug, has been conditionally approved in China. The drug is developed by US-based Yingli Pharma, a firm focused on developing products for both the China and US markets. The intended indication for linperlisib is recurrent\/refractory (R\/R) follicular lymphoma (FL). Hengrui Medicine will assist in the commercialization of the drug in China.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=24445\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NMPA Conditionally Approves Yingli Pharma's Linperlisib for Lymphoma\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=24445\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2022-11-10T07:53:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-31T07:55:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=24445#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=24445\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"NMPA Conditionally Approves Yingli Pharma’s Linperlisib for Lymphoma\",\"datePublished\":\"2022-11-10T07:53:00+00:00\",\"dateModified\":\"2025-01-31T07:55:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=24445\"},\"wordCount\":252,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Cancer\",\"Product approvals\",\"Yingli Pharma\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=24445#respond\"]}],\"copyrightYear\":\"2022\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=24445\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=24445\",\"name\":\"NMPA Conditionally Approves Yingli Pharma's Linperlisib for Lymphoma - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2022-11-10T07:53:00+00:00\",\"dateModified\":\"2025-01-31T07:55:30+00:00\",\"description\":\"The National Medical Products Administration (NMPA) website indicates that linperlisib, a Category 1 anti-tumor drug, has been conditionally approved in China. The drug is developed by US-based Yingli Pharma, a firm focused on developing products for both the China and US markets. The intended indication for linperlisib is recurrent\\\/refractory (R\\\/R) follicular lymphoma (FL). Hengrui Medicine will assist in the commercialization of the drug in China.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=24445#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=24445\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=24445#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NMPA Conditionally Approves Yingli Pharma’s Linperlisib for Lymphoma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"NMPA Conditionally Approves Yingli Pharma's Linperlisib for Lymphoma - Insight, China's Pharmaceutical Industry","description":"The National Medical Products Administration (NMPA) website indicates that linperlisib, a Category 1 anti-tumor drug, has been conditionally approved in China. The drug is developed by US-based Yingli Pharma, a firm focused on developing products for both the China and US markets. The intended indication for linperlisib is recurrent\/refractory (R\/R) follicular lymphoma (FL). Hengrui Medicine will assist in the commercialization of the drug in China.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=24445","og_locale":"en_US","og_type":"article","og_title":"NMPA Conditionally Approves Yingli Pharma's Linperlisib for Lymphoma","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=24445","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2022-11-10T07:53:00+00:00","article_modified_time":"2025-01-31T07:55:30+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=24445#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=24445"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"NMPA Conditionally Approves Yingli Pharma’s Linperlisib for Lymphoma","datePublished":"2022-11-10T07:53:00+00:00","dateModified":"2025-01-31T07:55:30+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=24445"},"wordCount":252,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Cancer","Product approvals","Yingli Pharma"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=24445#respond"]}],"copyrightYear":"2022","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=24445","url":"https:\/\/flcube.com\/?p=24445","name":"NMPA Conditionally Approves Yingli Pharma's Linperlisib for Lymphoma - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2022-11-10T07:53:00+00:00","dateModified":"2025-01-31T07:55:30+00:00","description":"The National Medical Products Administration (NMPA) website indicates that linperlisib, a Category 1 anti-tumor drug, has been conditionally approved in China. The drug is developed by US-based Yingli Pharma, a firm focused on developing products for both the China and US markets. The intended indication for linperlisib is recurrent\/refractory (R\/R) follicular lymphoma (FL). Hengrui Medicine will assist in the commercialization of the drug in China.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=24445#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=24445"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=24445#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"NMPA Conditionally Approves Yingli Pharma’s Linperlisib for Lymphoma"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/24445","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=24445"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/24445\/revisions"}],"predecessor-version":[{"id":24446,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/24445\/revisions\/24446"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=24445"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=24445"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=24445"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}